Funding supports Sorrento's staph infection work

Sorrento Therapeutics a two-year, $600,000 grant from the National Institute of Allergy and Infectious Diseases to support the company's develoment of antibody therapeutics and vaccines for Staph infections. The grant will help fund Phase I studies and could eventually lead to funding for Phase II trials. Article

Suggested Articles

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.

Ebola has claimed thousands of lives in recent outbreaks, but now the world has a licensed vaccine option in Merck's Ervebo.

Cosette Pharmaceuticals which was formed in December with a deal for dermatology projects has gone back to G&W Labs for a liquids plant.